Trial Profile
A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity Who Are Treated With Dysport
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- 26 Feb 2022 Results evaluating the effect of abobotulinumtoxinA treatment on lower extremity spasticity, walking ability and quality of life (QoL) through 20 weeks of treatment, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022
- 17 Jul 2018 New trial record